A cow antibody blocks CD4 (Viral Genetics, Inc)
Mort Zuckerman
Durlan...@yale.edu, Aa...@columbia.edu, gary_w...@nymc.edu,
scientifi...@ostp.gov, pkru...@princeton.edu,
Stanle...@fiu.edu, emcsw...@niaid.nih.gov, afa...@niaid.nih.gov,
Spin...@yahoogroups.com, kshe...@calea.org, fit...@gmail.com,
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
michae...@po.state.ct.us, con...@po.state.ct.us, executive-
edi...@nytimes.com, managin...@nytimes.com, news-
ti...@nytimes.com, biz...@nytimes.com, for...@nytimes.com,
nati...@nytimes.com, dv...@cdc.gov, brigidc...@optonline.net,
tr...@hotmail.com, illino...@aol.com, jle...@courant.com,
tinaj...@yahoo.com, jhorn...@fff.org, thomas...@usdoj.gov,
thoma...@po.state.ct.us, kur...@washpost.com,
georg...@washpost.com, p...@allegorypress.com,
commissi...@po.state.ct.us, brans...@comcast.net,
vts...@comcast.net, o...@po.state.ct.us, freet...@charter.net,
scott....@po.state.ct.us, govern...@po.state.ct.us,
attorney...@po.state.ct.us, randall...@usdoj.gov,
Robert....@yale.edu, edi...@greenwich-post.com,
harol...@yale.edu, sedm...@nswbc.org, rrmcg...@aol.com,
fr...@nytimes.com, dpr...@stmartin.edu, saint....@sbcglobal.net
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, afa...@niaid.nih.gov,
bmi...@newstimes.com, tr...@hotmail.com, rast...@aol.com,
billc...@gmail.com, amcg...@rms-law.com, rjmu...@aol.com,
paulcrai...@yahoo.com, criminal...@usdoj.gov,
karla.d...@usdoj.gov, christophe...@usdoj.gov,
richar...@yale.edu, harol...@yale.edu, james.p...@yale.edu,
inq...@aldf.com, ly...@idsociety.org, meganm...@theatlantic.com
Subject: A cow antibody blocks CD4 (Viral Genetics, Inc)
Date: Apr 12, 2010 1:50 PM
Splainer for the following
press release:
http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed&uid=19692465
A cow antibody blocks the HIV
co-receptor CD4:
http://www.ncbi.nlm.nih.gov/pubmed/19692465
Wow :o
Now they say they want to study
the anti-apoptosis mechanisms associated
with LYMErix (the production of the New
Great Imitators: MS, ALS, Cancer, Transverse
Myelitis, etc). I can't see how one could
get rid of the badly cloned immortalized B
cells that is characteristic of LYMErix disease
without something like leukaphoresis.
======================
http://www.marketwatch.com/story/uccs-and-texas-am-health-science-center-join-to-advance-disease-treatment-2010-04-12?reflink=MW_news_stmp
press release
April 12, 2010, 6:30 a.m. EDT · Recommend · Post:
UCCS and Texas A&M Health Science Center Join to Advance Disease
Treatment
SAN MARINO, Calif., Apr 12, 2010 (BUSINESS WIRE) -- The University of
Colorado at Colorado Springs will work collaboratively with the Texas
A&M Health Science Center in the areas of bioenergetics, immunology
and cell life, according to a memorandum of understanding between the
two schools announced Monday, April 10.
Nancy W. Dickey, M.D., president of the Texas A&M Health Science
Center and vice chancellor for health affairs for The Texas A&M
University System, and Pam Shockley-Zalabak, chancellor, UCCS, signed
the memorandum of understanding that will promote collaborative
research between the two institutions. Through their collaborative
activities, the universities intend to advance the scientific study
and understanding of cell metabolism, cell communication, and
programmed cell death that is central to the treatment and cure of
such diseases as cancer, HIV/AIDS, Lyme disease and others.
"I am pleased to collaborate with such a significant research
institution as the Texas A&M Health Science Center to unlock the
mysteries of illnesses that affect every segment of society," Shockley-
Zalabak said. "By joining forces, I believe our efforts will be
stronger."
UCCS has established the CU Institute of Bioenergetics and Immunology
to support a multidisciplinary approach to understanding cellular
metabolism (choice of fuel, energy production, storage and
consumption) and cellular communication. The HSC College of Medicine
has established a multidisciplinary research program in its Department
of Surgery that will study programmed cell death.
M. Karen Newell, Ph.D., formerly the Markert Professor of Biology at
UCCS and director of the CU Institute of Bioenergetics, has joined the
faculty at the HSC-College of Medicine, where she will hold the
Raleigh R. White Endowed Chair in Surgical Research at Scott & White
and lead the programmed cell death research program. Under the terms
of the memorandum of understanding, Newell will continue to provide
guidance and scientific direction to the CU Institute of Bioenergetics
and Immunology and will advise on future UCCS investment in the
institute. Newell also will guide the collaborative activities of the
two institutions. Under Newell's leadership, the universities'
collaborative activities may include sharing faculty research
expertise, laboratory space, equipment, administrative support, and
financial resources.
Newell said, "It's an honor to be able to coordinate research efforts
with two such highly respected institutions. CU has a deep
understanding of how this technology regarding cell metabolism and
treatments for autoimmune diseases was developed, where it is headed
and the benefits it will deliver. My new colleagues at the Texas A&M
Health Science Center will contribute fresh insight and expertise.
This partnership is the best possible way to ensure that these
initiatives move forward successfully and that the technologies reach
their full potential."
Viral Genetics, Inc., has entered into license agreements for
discoveries resulting from Newell's work at CU. Haig Keledjian,
president of Viral Genetics (OTC:VRAL.PK), said of the newly formed
collaboration, "We now have the resources of two leading universities
behind our research team. This joint effort will provide Dr. Newell's
very important work with the support it deserves. Since we licensed
Dr. Newell's technology years ago, we have witnessed many
breakthroughs. With her extraordinary ability, we have very high hopes
of developing treatments for the multiple diseases she is working on.
We are 100 percent behind Dr. Newell and this collaboration that
offers increased hope for people with many debilitating and life-
threatening diseases."
Keledjian also announced Viral Genetics' intention to establish a
physical presence in both Colorado Springs and Georgetown, Texas, to
support the continued collaborative and individual research efforts of
the two institutions.
Headquartered in San Marino, Calif., Viral Genetics discovers and
develops drug therapies to treat infectious, autoimmune and
immunological deficiency disorders using its targeted peptide
technology (TPT), metabolic disruption technology (MDT) and thymus
nuclear protein compound (TNP). Viral Genetics has optioned the
exclusive right to develop any and all drug therapies based on TPT and
MDT technology through an agreement with the University of Colorado
and V-Clip Pharmaceuticals (a Viral Genetics subsidiary.) Viral
Genetics has formed a wholly owned subsidiary, MetaCytoLytics, Inc, to
advance its research into MDT. Online at www.viralgenetics.com.
The Texas A&M Health Science Center provides the state with health
education, outreach and research through campuses in Bryan-College
Station, Dallas, Temple, Houston, Round Rock, Kingsville, Corpus
Christi and McAllen. Its six colleges are the Baylor College of
Dentistry, the College of Medicine, the College of Nursing, the
Graduate School of Biomedical Sciences, the Irma Lerma Rangel College
of Pharmacy and the School of Rural Public Health. Other units include
the Institute of Biosciences and Technology and the Coastal Bend
Health Education Center. For more information, visit http://tamhsc.edu/.
A member of the three campus University of Colorado System, UCCS is
located on Austin Bluffs Parkway in Colorado Springs and is one of the
fastest growing universities in the nation. The university offers 34
bachelor's degrees, 19 master's and five doctoral degrees. The campus
enrolls about 8,500 students annually. For more information, visit
www.uccs.edu.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:
This news release contains forward-looking statements that involve
risks and uncertainties associated with financial projections,
budgets, milestone timelines, clinical development, regulatory
approvals, and other risks described by Viral Genetics, Inc. from time
to time in its periodic reports filed with the SEC. None of Viral
Genetics' drug compounds are approved by the US Food and Drug
Administration or by any comparable regulatory agencies elsewhere in
the world. While Viral Genetics believes that the forward-looking
statements and underlying assumptions contained therein are
reasonable, any of the assumptions could be inaccurate, including, but
not limited to, the ability of Viral Genetics to establish the
efficacy of any of its drug therapies, including VGV-X, VGV-L, and VGV-
S, in the treatment of any disease or health condition, the
development of studies and strategies leading to commercialization of
those drug compounds in the United States, the obtaining of funding
required to carry out the development plan, the completion of studies
and tests on time or at all, and the successful outcome of such
studies or tests. Therefore, there can be no assurance that the
forward-looking statements included in this release will prove to be
accurate. In light of the significant uncertainties inherent in the
forward-looking statements included herein, the forward-looking
statements should not be regarded as a representation by Viral
Genetics or any other person that the objectives and plans of Viral
Genetics will be achieved.
SOURCE: Viral Genetics, Inc.
"[Real] scientists are *fiercely* independent. That's the good
news."-- NIH's Top Fool, Anthony Fauci